The DANCER study (Dose-Ranging Assessment International Clinical Evaluation of Rituximab in RA) evaluated the safety and efficacy in two doses of Rituxan
in combination with methotrexate
. Also studied was the role of corticosteroids
. The DANCER results indicated that Rituxan provided significant improvement in rheumatoid arthritis
symptoms compared to placebo, regardless of the dose. Read more about the Rituxan results.
UPDATE: On 03/01/2006, Rituxan (rituximab) was FDA approved to be used in combination with methotrexate to treat rheumatoid arthritis by reducing the signs and symptoms in adult patients who have moderately-to-severely active rheumatoid arthritis and have failed one or more anti-TNF drugs e.g. Enbrel (etanercept), Remicade (infliximab), or Humira (adalimumab).